First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors by David Turner, Antoine Italiano, Victor Moreno, Steven Hirschfeld, Juan Martin-Liberal, Michele Maio, Todd M Bauer, Christophe Le Tourneau, Danny Rischin, Catherine Ellis, Eric Angevin, Aaron Hansen, Helen Zhou, Ivan Diaz-Padilla, Frans Opdam, Sapna Yadavilli, Marc Ballas

Get full text